Related Experiment Videos
Neuroblastoma: the case for screening infants in North America
Insights
Early detection of neuroblastoma in infants through mass screening for urinary homovanillic acid and vanillylmandelic acid shows promise. This approach could significantly reduce childhood cancer mortality in the United States.
Area of Science:
- Pediatric Oncology
- Biomarker Detection
- Public Health Screening
Background:
- Neuroblastoma is a significant childhood cancer with a high incidence.
- Early diagnosis and treatment are crucial for curability.
- Tumor markers like homovanillic acid and vanillylmandelic acid are key indicators.
Purpose of the Study:
- To describe advances in infant screening for neuroblastoma.
- To evaluate the effectiveness of mass screening programs.
- To estimate the potential impact of screening on mortality rates.
Main Methods:
- Review of recent advancements in neuroblastoma screening techniques.
- Analysis of data from Japan's mass-screening program.
- Assessment of urinary homovanillic acid and vanillylmandelic acid as diagnostic markers.
Main Results:
- Urinary homovanillic acid and vanillylmandelic acid are effective markers for neuroblastoma.
- Mass screening programs demonstrate feasibility and potential for early detection.
- Estimated 260 lives could be saved annually in the US through screening.
Conclusions:
- Mass screening for neuroblastoma in infants is a viable strategy.
- Early detection via tumor marker analysis improves survival rates.
- Implementing screening programs can substantially decrease childhood cancer deaths.
Abstract:
Neuroblastoma is a disease in which easily measured tumor markers are excreted. It is curable when diagnosed in an early stage and at an early age, and it has a high incidence relative to other serious childhood diseases. Recent advances in screening infants for neuroblastoma by detection of urinary homovanillic acid and vanillylmandelic acid, the most useful markers of neuroblastoma, are described. Based on results from Japan's mass-screening program and on the authors' observations, it is estimated that mass screening for neuroblastoma could save 260 lives annually in the United States.